Genasense shown to enhance the anti-lymphoma activity of Velcade and Rituxan

Dec 5 2004

Genta Incorporated announced that two new studies have shown that Genasense (oblimersen sodium) Injection, the Company's lead anticancer drug, showed synergistic activity with both bortezomib (Velcade; Millennium Pharmaceuticals, Inc.) and rituximab (Rituxan; Genentech, Idec) in experimental models of B-cell non-Hodgkin's lymphoma (NHL).

The data were presented this weekend in sessions at the annual meeting of the American Society of Hematology (ASH) in San Diego, CA.

In the first study, investigators from Roswell Park Cancer Institute showed that Genasense or rituximab used alone significantly increased mean survival of mice implanted with NHL (by 130% and 170%, respectively, compared with untreated controls). Surprisingly, a treatment schedule of Genasense followed by rituximab yielded results similar to Genasense used alone, whereas a schedule of rituximab followed by Genasense increased mean survival by 240%. However, a schedule of concurrent treatment with Genasense and rituximab used together maximized the antitumor activity and increased mean survival by 400%.

In a second study, investigators from Memorial Sloan-Kettering Cancer Center and Roswell Park Cancer Institute collaborated on a study of Genasense plus bortezomib and cyclophosphamide using two models of experimental NHL. In the initial studies, the combination of Genasense (one dose pre-treatment, and 3 concurrent doses) plus bortezomib was superior to either agent used alone, and effectiveness of the combination was observed at one-quarter of the usual bortezomib dose. The Genasense/bortezomib combination was equivalent to treatment with high-dose cyclophosphamide, but none of the treatments were shown to be curative. However, the three drugs used together -- but not any pair of drugs used alone -- were found to be curative, but only when Genasense preceded cyclophosphamide, followed by bortezomib.

"Most prior studies of Genasense with standard chemotherapeutic agents have suggested that pre-treatment with Genasense -- rather than concurrent or subsequent treatment -- maximizes the chemosensitizing activity," said Dr. Bob Brown, Genta's Vice President, Research and Technology. "These two studies present compelling information that the newer generation of highly targeted agents also synergize with Genasense, but also that they require careful testing for schedule-dependency in order to maximize the anticancer activity."

Genasense inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced apoptosis (programmed cell death). By reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatments. Genta is pursuing a broad clinical development program with Genasense evaluating its potential to treat various forms of cancer.